2590-0048

Clinical Hematology International

SAABRON PRESS

View prefix report (10.46989)

Health Score

0 Fair

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 140 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact140 DOIs
2

Add abstracts to 124 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact124 DOIs
3

Deposit reference lists for 94 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Medium impact94 DOIs

DOIs for this ISSN

Showing the top 5 of 229 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Summary of Scientific and Statistical Methods, Study Endpoin… (10.2991/chi.d.191207.001)
Abstract References ORCID License
197.31 93
2 Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute… (10.2991/chi.d.190310.001)
Abstract References ORCID License
174.82 55
3 Cold Agglutinin Disease (10.2991/chi.k.200706.001)
Abstract References ORCID License
165.32 44
4 Fecal Microbiota Transplantation for Treatment of Acute Graf… (10.2991/chi.d.190316.002)
Abstract References ORCID License
151.85 32
5 Endothelial Dysfunction in Hematopoietic Cell Transplantatio… (10.2991/chi.d.190317.001)
Abstract References ORCID License
151.85 32
6 The Many Faces of Cytokine Release Syndrome-Related Coagulop… (10.2991/chi.k.210117.001)
Abstract References ORCID License
151.85 32
7 CART Cell Toxicities: New Insight into Mechanisms and Manage… (10.2991/chi.k.201108.001)
Abstract References ORCID License
149.14 30
8 Current Status and Future Directions in Graft-<i>Versus</i>-… (10.2991/chi.d.200115.001)
Abstract References ORCID License
144.72 27
9 The CD34<sup>+</sup> Cell Dose Matters in Hematopoietic Stem… (10.2991/chi.d.200221.001)
Abstract References ORCID License
141.50 25
10 Gastrointestinal Complications after Allogeneic Hematopoieti… (10.2991/chi.k.210826.001)
Abstract References ORCID License
138.02 23
11 Relapse and Resistance to CAR-T Cells and Blinatumomab in He… (10.2991/chi.d.190219.001)
Abstract References ORCID License
136.17 22
12 Haploidentical Hematopoietic Stem Cell Transplantation Follo… (10.2991/chi.d.200405.001)
Abstract References ORCID License
136.17 22
13 Machine Learning Applications in the Diagnosis of Benign and… (10.2991/chi.k.201130.001)
Abstract References ORCID License
136.17 22
14 Polatuzumab Vedotin: Current Role and Future Applications in… (10.2991/chi.k.210305.001)
Abstract References ORCID License
134.24 21
15 History of Acute Promyelocytic Leukemia (10.2991/chi.k.210703.001)
Abstract References ORCID License
134.24 21
16 Current Status and Perspectives of Irradiation-Based Conditi… (10.2991/chi.d.190218.002)
Abstract References ORCID License
132.22 20
17 What’s Important and New in Hemochromatosis? (10.2991/chi.k.200726.001)
Abstract References ORCID License
127.88 18
18 Conditioning Regimens for Frail Patients with Acute Leukemia… (10.2991/chi.k.210731.001)
Abstract References ORCID License
125.53 17
19 High Sensitivity Troponin T and NT-proBNP in Patients Receiv… (10.2991/chi.k.210718.001)
Abstract References ORCID License
123.04 16
20 Challenges in Conducting Studies in Chronic Graft-versus-Hos… (10.2991/chi.d.190314.001)
Abstract References ORCID License
114.61 13
21 Plasma Cell Leukemia – Facts and Controversies: More Questio… (10.2991/chi.k.200706.002)
Abstract References ORCID License
107.92 11
22 History and Development of Autologous Stem Cell Transplantat… (10.2991/chi.k.210703.002)
Abstract References ORCID License
107.92 11
23 Management of AML Beyond “3 + 7” in 2019 (10.2991/chi.d.190316.001)
Abstract References ORCID License
104.14 10
24 Managing Endocrine Disorders in Adults After Hematopoietic S… (10.2991/chi.d.190917.001)
Abstract References ORCID License
104.14 10
25 Treatment of Adult Patients with Relapsed/Refractory B-Cell… (10.2991/chi.d.190503.002)
Abstract References ORCID License
100.00 9
26 Moving Toward Continuous Therapy in Multiple Myeloma (10.2991/chi.d.191101.001)
Abstract References ORCID License
100.00 9
27 How to Make the Right Diagnosis in Neutropenia (10.2991/chi.k.210216.001)
Abstract References ORCID License
100.00 9
28 Therapeutic Use of Convalescent Plasma in COVID-19 Infected… (10.2991/chi.k.210403.001)
Abstract References ORCID License
95.42 8
29 How I Use Measurable Residual Disease in the Clinical Manage… (10.2991/chi.k.211119.001)
Abstract References ORCID License
95.42 8
30 Comparison of Conventional Cyclophosphamide <i>versus</i> Fl… (10.2991/chi.d.200426.001)
Abstract References ORCID License
90.31 7
31 Association of Patient-Reported Physical Activity on Allogen… (10.2991/chi.k.210221.001)
Abstract References ORCID License
90.31 7
32 Allogeneic Stem Cell Transplantation with a Novel Reduced In… (10.2991/chi.k.210529.001)
Abstract References ORCID License
90.31 7
33 Therapeutic Approaches for Blastic Plasmacytoid Dendritic Ce… (10.2991/chi.d.190218.001)
Abstract References ORCID License
84.51 6
34 The Evolving Landscape of Myelodysplastic Syndrome Prognosti… (10.2991/chi.d.200408.001)
Abstract References ORCID License
84.51 6
35 Predicting Immuno-Metabolic Complications After Allogeneic H… (10.2991/chi.d.200506.002)
Abstract References ORCID License
84.51 6
36 B Cell Deficiency in Patients with Relapsed and Refractory A… (10.2991/chi.k.200712.001)
Abstract References ORCID License
84.51 6
37 Overview of approved CAR-T products and utility in clinical… (10.46989/001c.124277)
Abstract ORCID
83.14 45
38 The Clinical Course of Multiple Myeloma in the Era of Novel… (10.2991/chi.d.190805.002)
Abstract References ORCID License
77.82 5
39 Timed Sequential Salvage Chemotherapy for Relapsed or Refrac… (10.2991/chi.d.191128.001)
Abstract References ORCID License
77.82 5
40 Framingham Risk Score Is an Ineffective Screening Strategy f… (10.2991/chi.d.200508.001)
Abstract References ORCID License
77.82 5
41 Monocyte Reconstitution and Gut Microbiota Composition after… (10.2991/chi.k.201108.002)
Abstract References ORCID License
77.82 5
42 Passive Immunity Should and Will Work for COVID-19 for Some… (10.2991/chi.k.210328.001)
Abstract References ORCID License
77.82 5
43 Red Blood Cell Distribution Width: Another Prognostic Factor… (10.2991/chi.k.210404.001)
Abstract References ORCID License
77.82 5
44 Baseline Photos and Confident Annotation Improve Automated D… (10.2991/chi.k.210704.001)
Abstract References ORCID License
77.82 5
45 CD3/CD19 Depletion for T-cell Reduction of Allogeneic Transp… (10.2991/chi.k.210725.001)
Abstract References ORCID License
77.82 5
46 Idiopathic Aplastic Anemia: An Update (10.2991/chi.d.190321.002)
Abstract References ORCID License
69.90 4
47 Low-Dose Acyclovir Prophylaxis for Varicella zoster Reactiva… (10.2991/chi.d.190329.001)
Abstract References ORCID License
69.90 4
48 Clinical Advancement and Challenges of <i>ex vivo</i> Expans… (10.2991/chi.d.191121.001)
Abstract References ORCID License
69.90 4
49 Maintenance Strategies Post-Autologous Stem Cell Transplanta… (10.2991/chi.d.200502.001)
Abstract References ORCID License
69.90 4
50 Safety and Efficacy of Haploidentical Peripheral Blood Stem… (10.2991/chi.d.190316.003)
Abstract References ORCID License
60.21 3